Business Context and Reporting Period
This Form 8-K filing by Corbus Pharmaceuticals Holdings, Inc. (CRBP) reports corporate governance changes effective March 5, 2020, and March 6, 2020. The report details the resignation of a director and the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on personnel and governance matters.
Material Changes
- Director Resignation: Paris Panayiotopoulos resigned from the Board effective March 6, 2020. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Committee Reassignments: Rachelle Jacques was appointed to the Audit Committee, Compensation Committee, and as a member and chair of the Nominating and Corporate Governance Committee.
- New Director Appointment: Peter Salzmann, M.D., M.B.A., was appointed to the Board on March 6, 2020. Dr. Salzmann brings extensive experience from Immunovant, Inc. and Eli Lilly and Company.
Compensation and Governance Details
Dr. Salzmann's compensation package includes:
- An initial option grant to purchase 66,600 shares of Common Stock.
- An annual cash retainer fee of $35,000 (pro-rated for the current year).
- An annual stock option grant.
- Entry into a standard Indemnification Agreement covering legal expenses and liabilities arising from his service as a director.
A press release regarding these changes was issued on March 10, 2020, under Regulation FD.
Investor Verification Checklist
- Verify the effective dates of the resignation and appointment (March 6, 2020).
- Confirm the specific committee assignments for Rachelle Jacques.
- Review the terms of the Indemnification Agreement filed as Exhibit 10.15 to the S-1 Amendment.
- Check the press release (Exhibit 99.1) for additional context on the Board's strategic direction.